Role of Thioredoxin in Age-Related Hypertension

  • Kumuda C. Das
  • Venkatesh Kundumani-Sridharan
  • Jaganathan Subramani
Hypertension and Obesity (E Reisin, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Hypertension and Obesity


Purpose of Review

Although the roles of oxidant stress and redox perturbations in hypertension have been the subject of several reviews, role of thioredoxin (Trx), a major cellular redox protein in age-related hypertension remains inadequately reviewed. The purpose of this review is to bring readers up-to-date with current understanding of the role of thioredoxin in age-related hypertension.

Recent Findings

Age-related hypertension is a major underlying cause of several cardiovascular disorders, and therefore, intensive management of blood pressure is indicated in most patients with cardiovascular complications. Recent studies have shown that age-related hypertension was reversed and remained lowered for a prolonged period in mice with higher levels of human Trx (Trx-Tg). Additionally, injection of human recombinant Trx (rhTrx) decreased hypertension in aged wild-type mice that lasted for several days. Both Trx-Tg and aged wild-type mice injected with rhTrx were normotensive, showed increased NO production, decreased arterial stiffness, and increased vascular relaxation. These studies suggest that rhTrx could potentially be a therapeutic molecule to reverse age-related hypertension in humans. The reversal of age-related hypertension by restoring proteins that have undergone age-related modification is conceptually novel in the treatment of hypertension.


Trx reverses age-related hypertension via maintaining vascular redox homeostasis, regenerating critical vasoregulatory proteins oxidized due to advancing age, and restoring native function of proteins that have undergone age-related modifications with loss-of function. Recent studies demonstrate that Trx is a promising molecule that may ameliorate or reverse age-related hypertension in older adults.


Hypertension Thioredoxin Age Redox Glutathionylation eNOS 


Compliance with Ethical Standards

Conflict of Interest

The authors declare no conflicts of interest relevant to this manuscript. A patent application (US 5/323,545 UT Health Sciences Center at Tyler) for use of Thioredoxin in the treatment of high blood pressure is currently pending with the US patent and Trademark Office.

Human and Animal Rights and Informed Consent

This article does not contain any studies with humans or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Fujimoto H, Kobayashi H, Ohno M. Age-induced reduction in mitochondrial manganese superoxide dismutase activity and tolerance of macrophages against apoptosis induced by oxidized low density lipoprotein. Circ J. 2010;74(2):353–60. Scholar
  2. 2.
    Pansarasa O, Bertorelli L, Vecchiet J, Felzani G, Marzatico F. Age-dependent changes of antioxidant activities and markers of free radical damage in human skeletal muscle. Free Radic Biol Med. 1999;27(5–6):617–22. Scholar
  3. 3.
    • Pawluk H, Pawluk R, Robaczewska J, Kedziora-Kornatowska K, Kedziora J. Biomarkers of antioxidant status and lipid peroxidation in elderly patients with hypertension. Redox Rep. 2017;22:542–546. This review shows high levels of oxidative markers in hypertensive patients linking aged-related oxidation to hypertension in humans. PubMedCrossRefGoogle Scholar
  4. 4.
    • de Almeida A, Ribeiro TP, de Medeiros IA. Aging: molecular pathways and implications on the cardiovascular system. Oxidative Med Cell Longev. 2017;2017:7941563. This article reviewed age-related oxidative pathways that contibutes to cardiovascular diseases. Google Scholar
  5. 5.
    • Paneni F, Diaz Canestro C, Libby P, Luscher TF, Camici GG. The Aging Cardiovascular System: Understanding It at the Cellular and Clinical Levels. J Am Coll Cardiol. 2017;69(15):1952–67. This review describes clinically identifiable factors associated with aging cardiovascular system and possible molecular mechanisms related to age related changes in heart and vasculature. PubMedCrossRefGoogle Scholar
  6. 6.
    Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The seventh report of the joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA. 2003;289(19):2560–72. PubMedCrossRefGoogle Scholar
  7. 7.
    Wolf-Maier K, Cooper RS, Banegas JR, Giampaoli S, Hense HW, Joffres M, et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA. 2003;289(18):2363–9. Scholar
  8. 8.
    •• Pimenta E, Oparil S. Management of hypertension in the elderly. Nat Rev Cardiol. 2012;9(5):286–96. This review summarizes age related primary and secondary factors important for age-related hypertension. The authors also discuss possible treatment strategies. PubMedCrossRefGoogle Scholar
  9. 9.
    Rahimi K, Emdin CA, MacMahon S. The epidemiology of blood pressure and its worldwide management. Circ Res. 2015;116(6):925–36. Scholar
  10. 10.
    Chen HZ, Wang F, Gao P, Pei JF, Liu Y, Xu TT, et al. Age-associated Sirtuin 1 reduction in vascular smooth muscle links vascular senescence and inflammation to abdominal aortic aneurysm. Circ Res. 2016;119(10):1076–88. PubMedCrossRefGoogle Scholar
  11. 11.
    Celermajer DS, Sorensen KE, Bull C, Robinson J, Deanfield JE. Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. J Am Coll Cardiol. 1994;24(6):1468–74. Scholar
  12. 12.
    Wallace SM, Yasmin, McEniery CM, Maki-Petaja KM, Booth AD, Cockcroft JR, et al. Isolated systolic hypertension is characterized by increased aortic stiffness and endothelial dysfunction. Hypertension. 2007;50(1):228–33. Scholar
  13. 13.
    • Avolio A. Arterial Stiffness. Pulse (Basel). 2013;1(1):14–28. This review explains arterial stiffness from a mechanical perspective and discusses active and passive mechanisms involved in development of arterial stiffness.CrossRefGoogle Scholar
  14. 14.
    •• Kaess BM, Rong J, Larson MG, Hamburg NM, Vita JA, Levy D, et al. Aortic stiffness, blood pressure progression, and incident hypertension. JAMA. 2012;308(9):875–81. This study shows correlation between aortic stiffness and pulse wave velocity to predict development of systolic hypertension. PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Harvey A, Montezano AC, Touyz RM. Vascular biology of ageing-implications in hypertension. J Mol Cell Cardiol. 2015;83:112–21. Scholar
  16. 16.
    • Payne RA, Wilkinson IB, Webb DJ. Arterial stiffness and hypertension: emerging concepts. Hypertension. 2010;55(1):9–14. This review explains underlying development of arterial stiffness, arterial stiffness measurement methods, its relevance to clinical diagnosis of hypertension and possible treatment strategies.PubMedCrossRefGoogle Scholar
  17. 17.
    Ferruzzi J, Bersi MR, Mecham RP, Ramirez F, Yanagisawa H, Tellides G, et al. Loss of elastic fiber integrity compromises common carotid artery function: implications for vascular aging. Artery Res. 2016;14:41–52. Scholar
  18. 18.
    Dao HH, Essalihi R, Bouvet C, Moreau P. Evolution and modulation of age-related medial elastocalcinosis: impact on large artery stiffness and isolated systolic hypertension. Cardiovasc Res. 2005;66(2):307–17. Scholar
  19. 19.
    Laurent S, Boutouyrie P. Recent advances in arterial stiffness and wave reflection in human hypertension. Hypertension. 2007;49(6):1202–6. Scholar
  20. 20.
    Duca L, Blaise S, Romier B, Laffargue M, Gayral S, El Btaouri H, et al. Matrix ageing and vascular impacts: focus on elastin fragmentation. Cardiovasc Res. 2016;110(3):298–308. Scholar
  21. 21.
    Flamant M, Placier S, Dubroca C, Esposito B, Lopes I, Chatziantoniou C, et al. Role of matrix metalloproteinases in early hypertensive vascular remodeling. Hypertension. 2007;50(1):212–8. Scholar
  22. 22.
    McEniery CM, McDonnell BJ, So A, Aitken S, Bolton CE, Munnery M, et al. Aortic calcification is associated with aortic stiffness and isolated systolic hypertension in healthy individuals. Hypertension. 2009;53(3):524–31. Scholar
  23. 23.
    • Sharman JE, Boutouyrie P, Laurent S. Arterial (Aortic) stiffness in patients with resistant hypertension: from assessment to treatment. Curr Hypertens Rep. 2017;19(1):2. This review links arterial stiffness to resistance hypertension and possible treatement strategies. PubMedCrossRefGoogle Scholar
  24. 24.
    Celermajer DS, Sorensen KE, Spiegelhalter DJ, Georgakopoulos D, Robinson J, Deanfield JE. Aging is associated with endothelial dysfunction in healthy men years before the age-related decline in women. J Am Coll Cardiol. 1994;24(2):471–6. Scholar
  25. 25.
    Oelze M, Kroller-Schon S, Steven S, Lubos E, Doppler C, Hausding M, et al. Glutathione peroxidase-1 deficiency potentiates dysregulatory modifications of endothelial nitric oxide synthase and vascular dysfunction in aging. Hypertension. 2014;63(2):390–6. Scholar
  26. 26.
    •• Higashi Y, Kihara Y, Noma K. Endothelial dysfunction and hypertension in aging. Hypertens Res. 2012;35(11):1039–47. This review article summarizes factors associated with endothelial dysfunction and their involvement in aging and hypertension.PubMedCrossRefGoogle Scholar
  27. 27.
    Seals DR, Jablonski KL, Donato AJ. Aging and vascular endothelial function in humans. Clin Sci (Lond). 2011;120(9):357–75. Scholar
  28. 28.
    • Montezano AC, Dulak-Lis M, Tsiropoulou S, Harvey A, Briones AM, Touyz RM. Oxidative stress and human hypertension: vascular mechanisms, biomarkers, and novel therapies. Can J Cardiol. 2015;31(5):631–41. Discusses our current understanding in oxidative stress and human hypertension.PubMedCrossRefGoogle Scholar
  29. 29.
    Daiber A, Di Lisa F, Oelze M, Kroller-Schon S, Steven S, Schulz E, et al. Crosstalk of mitochondria with NADPH oxidase via reactive oxygen and nitrogen species signalling and its role for vascular function. Br J Pharmacol. 2015;
  30. 30.
    Lassegue B, San Martin A, Griendling KK. Biochemistry, physiology, and pathophysiology of NADPH oxidases in the cardiovascular system. Circ Res. 2012;110(10):1364–90. Scholar
  31. 31.
    •• Hilgers RH, Kundumani-Sridharan V, Subramani J, Chen LC, Cuello LG, Rusch NJ, et al. Thioredoxin reverses age-related hypertension by chronically improving vascular redox and restoring eNOS function. Sci Transl Med. 2017;9(376):eaaf6094. This study demonstrates that high levels of Thioredoxin reverse age-related hypertension due to preservation of redox-related functions in the vessels.PubMedPubMedCentralCrossRefGoogle Scholar
  32. 32.
    Mikhed Y, Daiber A, Steven S. Mitochondrial oxidative stress, mitochondrial DNA damage and their role in age-related vascular dysfunction. Int J Mol Sci. 2015;16(7):15918–53. Scholar
  33. 33.
    Potje SR, Chen Z, Oliveira SDS, Bendhack LM, da Silva RS, Bonini MG, et al. Nitric oxide donor [Ru(terpy)(bdq)NO]3+ induces uncoupling and phosphorylation of endothelial nitric oxide synthase promoting oxidant production. Free Radic Biol Med. 2017;112:587–96. Scholar
  34. 34.
    Yang YM, Huang A, Kaley G, Sun D. eNOS uncoupling and endothelial dysfunction in aged vessels. Am J Physiol Heart Circ Physiol. 2009;297(5):H1829–36. Scholar
  35. 35.
    Hilgers RH, Das KC. Role of in vivo vascular redox in resistance arteries. Hypertension. 2015;65(1):130–9. PubMedCrossRefGoogle Scholar
  36. 36.
    • Sies H, Berndt C, Jones DP. Oxidative Stress. Annu Rev Biochem. 2017;86(1):715–48. This review describes about two sides of oxidative stress and how redox balance regulates cell signaling in health and diseases.PubMedCrossRefGoogle Scholar
  37. 37.
    Chen CA, De Pascali F, Basye A, Hemann C, Zweier JL. Redox modulation of endothelial nitric oxide synthase by glutaredoxin-1 through reversible oxidative post-translational modification. Biochemistry. 2013;52(38):6712–23. Scholar
  38. 38.
    Kang KT. Endothelium-derived relaxing factors of small resistance arteries in hypertension. Toxicol Res. 2014;30(3):141–8. Scholar
  39. 39.
    Ray R, Murdoch CE, Wang M, Santos CX, Zhang M, Alom-Ruiz S, et al. Endothelial Nox4 NADPH oxidase enhances vasodilatation and reduces blood pressure in vivo. Arterioscler Thromb Vasc Biol. 2011;31(6):1368–76. Scholar
  40. 40.
    Matoba T, Shimokawa H, Nakashima M, Hirakawa Y, Mukai Y, Hirano K, et al. Hydrogen peroxide is an endothelium-derived hyperpolarizing factor in mice. J Clin Invest. 2000;106(12):1521–30. Scholar
  41. 41.
    Muller-Delp JM, Gurovich AN, Christou DD, Leeuwenburgh C. Redox balance in the aging microcirculation: new friends, new foes, and new clinical directions. Microcirculation. 2012;19(1):19–28. PubMedCrossRefGoogle Scholar
  42. 42.
    Jones DP. Radical-free biology of oxidative stress. Am J Physiol Cell Physiol. 2008;295(4):C849–68. Scholar
  43. 43.
    • Go YM, Jones DP. Redox theory of aging: implications for health and disease. Clin Sci (Lond). 2017;131(14):1669–88. Reviews free radicals, aging and implications in health and disease.CrossRefGoogle Scholar
  44. 44.
    Laurent TC, Moore EC, Reichard P. Enzymatic synthesis of Deoxyribonucleotides. Iv. Isolation and characterization of Thioredoxin, the hydrogen donor from Escherichia Coli B. J Biol Chem. 1964;239:3436–44.PubMedGoogle Scholar
  45. 45.
    • Lu J, Holmgren A. The thioredoxin antioxidant system. Free Radic Biol Med. 2014;66:75–87. Scholar
  46. 46.
    Holmgren A, et al. Annu Rev Biochem. 1985;54:237–71.PubMedCrossRefGoogle Scholar
  47. 47.
    Haendeler J, Hoffmann J, Tischler V, Berk BC, Zeiher AM, Dimmeler S. Redox regulatory and anti-apoptotic functions of thioredoxin depend on S-nitrosylation at cysteine 69. Nat Cell Biol. 2002;4(10):743–9. Scholar
  48. 48.
    Haendeler J. Thioredoxin-1 and posttranslational modifications. Antioxid Redox Signal. 2006;8(9–10):1723–8. Scholar
  49. 49.
    Gasdaska JR, Kirkpatrick DL, Montfort W, Kuperus M, Hill SR, Berggren M, et al. Oxidative inactivation of thioredoxin as a cellular growth factor and protection by a Cys73-->Ser mutation. Biochem Pharmacol. 1996;52(11):1741–7.PubMedCrossRefGoogle Scholar
  50. 50.
    Hashemy SI, Holmgren A. Regulation of the catalytic activity and structure of human thioredoxin 1 via oxidation and S-nitrosylation of cysteine residues. J Biol Chem. 2008;283(32):21890–8. Scholar
  51. 51.
    Das KC, Das CK. Thioredoxin, a singlet oxygen quencher and hydroxyl radical scavenger: redox independent functions. Biochem Biophys Res Commun. 2000;277(2):443–7. Scholar
  52. 52.
    Das KC, Lewis-Molock Y, White CW. Elevation of manganese superoxide dismutase gene expression by thioredoxin. Am J Respir Cell Mol Biol. 1997;17(6):713–26. Scholar
  53. 53.
    •• Kundumani-Sridharan V, Subramani J, Das KC. Thioredoxin Activates MKK4-NFkappaB pathway in a redox-dependent manner to control manganese superoxide dismutase gene expression in endothelial cells. J Biol Chem. 2015;290(28):17505–19. This study demonstrates novel redox signaling mechanism of induction of important mitochondrial superoxide dismutase by thioredoxin.PubMedPubMedCentralCrossRefGoogle Scholar
  54. 54.
    Das KC, Pahl PM, Guo XL, White CW. Induction of peroxiredoxin gene expression by oxygen in lungs of newborn primates. Am J Respir Cell Mol Biol. 2001;25(2):226–32. Scholar
  55. 55.
    Berggren MI, Husbeck B, Samulitis B, Baker AF, Gallegos A, Powis G. Thioredoxin peroxidase-1 (peroxiredoxin-1) is increased in thioredoxin-1 transfected cells and results in enhanced protection against apoptosis caused by hydrogen peroxide but not by other agents including dexamethasone, etoposide, and doxorubicin. Arch Biochem Biophys. 2001;392(1):103–9. Scholar
  56. 56.
    Das KC, Muniyappa H. C-Jun-NH2 terminal kinase (JNK)-mediates AP-1 activation by thioredoxin: phosphorylation of cJun, JunB, and Fra-1. Mol Cell Biochem. 2010;337(1–2):53–63. Scholar
  57. 57.
    Holmgren A. Redox regulation by thioredoxin and thioredoxin reductase. Biofactors. 2000;11(1–2):63–4. Scholar
  58. 58.
    Lu J, Holmgren A. Thioredoxin system in cell death progression. Antioxid Redox Signal. 2012;17(12):1738–47. Scholar
  59. 59.
    Nonn L, Williams RR, Erickson RP, Powis G. The absence of mitochondrial thioredoxin 2 causes massive apoptosis, exencephaly, and early embryonic lethality in homozygous mice. Mol Cell Biol. 2003;23(3):916–22. Scholar
  60. 60.
    Widder JD, Fraccarollo D, Galuppo P, Hansen JM, Jones DP, Ertl G, et al. Attenuation of angiotensin II-induced vascular dysfunction and hypertension by overexpression of Thioredoxin 2. Hypertension. 2009;54(2):338–44. Scholar
  61. 61.
    Zhang H, Luo Y, Zhang W, He Y, Dai S, Zhang R, et al. Endothelial-specific expression of mitochondrial thioredoxin improves endothelial cell function and reduces atherosclerotic lesions. Am J Pathol. 2007;170(3):1108–20. Scholar
  62. 62.
    • Guzik TJ, Touyz RM. Oxidative Stress, Inflammation, and vascular aging in hypertension. Hypertension. 2017;70(4):660–7. This review describes that oxidative stress and inflammation are the key mechanisms of endothelial dysfunction and is a major risk factor for vascular diseases in aging.PubMedCrossRefGoogle Scholar
  63. 63.
    Harvey A, Montezano AC, Lopes RA, Rios F, Touyz RM. Vascular fibrosis in aging and hypertension: molecular mechanisms and clinical implications. Can J Cardiol. 2016;32(5):659–68. Scholar
  64. 64.
    Sun Z. Aging, arterial stiffness, and hypertension. Hypertension. 2015;65(2):252–6. Recent review on aging, stiffness and hypertension.PubMedCrossRefGoogle Scholar
  65. 65.
    Tan J, Hua Q, Xing X, Wen J, Liu R, Yang Z. Impact of the metalloproteinase-9/tissue inhibitor of metalloproteinase-1 system on large arterial stiffness in patients with essential hypertension. Hypertens Res. 2007;30(10):959–63. Scholar
  66. 66.
    Toth P, Tarantini S, Springo Z, Tucsek Z, Gautam T, Giles CB, et al. Aging exacerbates hypertension-induced cerebral microhemorrhages in mice: role of resveratrol treatment in vasoprotection. Aging Cell. 2015;14(3):400–8. Scholar
  67. 67.
    Wheeler JB, Mukherjee R, Stroud RE, Jones JA, Ikonomidis JS. Relation of murine thoracic aortic structural and cellular changes with aging to passive and active mechanical properties. J Am Heart Assoc. 2015;4(3):e001744. Scholar
  68. 68.
    Yasmin, McEniery CM, Wallace S, Dakham Z, Pulsalkar P, Maki-Petaja K, et al. Matrix metalloproteinase-9 (MMP-9), MMP-2, and serum elastase activity are associated with systolic hypertension and arterial stiffness. Arterioscler Thromb Vasc Biol. 2005;25(2):372. Scholar
  69. 69.
    Jiang L, Zhang J, Monticone RE, Telljohann R, Wu J, Wang M, et al. Calpain-1 regulation of matrix metalloproteinase 2 activity in vascular smooth muscle cells facilitates age-associated aortic wall calcification and fibrosis. Hypertension. 2012;60(5):1192–9. Scholar
  70. 70.
    Wang M, Zhang J, Telljohann R, Jiang L, Wu J, Monticone RE, et al. Chronic matrix metalloproteinase inhibition retards age-associated arterial proinflammation and increase in blood pressure. Hypertension. 2012;60(2):459–66. Scholar
  71. 71.
    Ceron CS, Rizzi E, Guimaraes DA, Martins-Oliveira A, Cau SB, Ramos J, et al. Time course involvement of matrix metalloproteinases in the vascular alterations of renovascular hypertension. Matrix Biol. 2012;31(4):261–70. Scholar
  72. 72.
    Sasaki T, Nakamura K, Sasada K, Okada S, Cheng XW, Suzuki T, et al. Matrix metalloproteinase-2 deficiency impairs aortic atherosclerotic calcification in ApoE-deficient mice. Atherosclerosis. 2013;227(1):43–50. Scholar
  73. 73.
    Wang M, Zhao D, Spinetti G, Zhang J, Jiang LQ, Pintus G, et al. Matrix metalloproteinase 2 activation of transforming growth factor-beta1 (TGF-beta1) and TGF-beta1-type II receptor signaling within the aged arterial wall. Arterioscler Thromb Vasc Biol. 2006;26(7):1503–9. Scholar
  74. 74.
    Farina AR, Tacconelli A, Cappabianca L, Masciulli MP, Holmgren A, Beckett GJ, et al. Thioredoxin alters the matrix metalloproteinase/tissue inhibitors of metalloproteinase balance and stimulates human SK-N-SH neuroblastoma cell invasion. Eur J Biochem. 2001;268(2):405–13. Scholar
  75. 75.
    Buechner N, Schroeder P, Jakob S, Kunze K, Maresch T, Calles C, et al. Changes of MMP-1 and collagen type Ialpha1 by UVA, UVB and IRA are differentially regulated by Trx-1. Exp Gerontol. 2008;43(7):633–7. Scholar
  76. 76.
    Aragao AZ, Nogueira ML, Granato DC, Simabuco FM, Honorato RV, Hoffman Z, et al. Identification of novel interaction between ADAM17 (a disintegrin and metalloprotease 17) and thioredoxin-1. J Biol Chem. 2012;287(51):43071–82. Scholar
  77. 77.
    Sueblinvong V, Mills ST, Neujahr DC, Go YM, Jones DP, Guidot DM. Nuclear Thioredoxin-1 overexpression attenuates alcohol-mediated Nrf2 signaling and lung fibrosis. Alcohol Clin Exp Res. 2016;40(9):1846–56. Scholar
  78. 78.
    El Hadri K, Mahmood DF, Couchie D, Jguirim-Souissi I, Genze F, Diderot V, et al. Thioredoxin-1 promotes anti-inflammatory macrophages of the M2 phenotype and antagonizes atherosclerosis. Arterioscler Thromb Vasc Biol. 2012;32(6):1445–52. Scholar
  79. 79.
    Vazquez-Padron RI, Lasko D, Li S, Louis L, Pestana IA, Pang M, et al. Aging exacerbates neointimal formation, and increases proliferation and reduces susceptibility to apoptosis of vascular smooth muscle cells in mice. J Vasc Surg. 2004;40(6):1199–207. Scholar
  80. 80.
    Dagnell M, Frijhoff J, Pader I, Augsten M, Boivin B, Xu J, et al. Selective activation of oxidized PTP1B by the thioredoxin system modulates PDGF-beta receptor tyrosine kinase signaling. Proc Natl Acad Sci U S A. 2013;110(33):13398–403. Scholar
  81. 81.
    Dagnell M, Pace PE, Cheng Q, Frijhoff J, Ostman A, Arner ESJ, et al. Thioredoxin reductase 1 and NADPH directly protect protein tyrosine phosphatase 1B from inactivation during H2O2 exposure. J Biol Chem. 2017;292(35):14371–80. Scholar
  82. 82.
    Schwertassek U, Haque A, Krishnan N, Greiner R, Weingarten L, Dick TP, et al. Reactivation of oxidized PTP1B and PTEN by thioredoxin 1. FEBS J. 2014;281(16):3545–58. PubMedPubMedCentralCrossRefGoogle Scholar
  83. 83.
    Zhou RH, Vendrov AE, Tchivilev I, Niu XL, Molnar KC, Rojas M, et al. Mitochondrial oxidative stress in aortic stiffening with age: the role of smooth muscle cell function. Arterioscler Thromb Vasc Biol. 2012;32(3):745–55. Scholar
  84. 84.
    Fleenor BS, Seals DR, Zigler ML, Sindler AL. Superoxide-lowering therapy with TEMPOL reverses arterial dysfunction with aging in mice. Aging Cell. 2012;11(2):269–76. Scholar
  85. 85.
    Das KC. Thioredoxin-deficient mice, a novel phenotype sensitive to ambient air and hypersensitive to hyperoxia-induced lung injury. Am J Physiol Lung Cell Mol Physiol. 2015;308(5):L429–42. Scholar
  86. 86.
    Lima B, Forrester MT, Hess DT, Stamler JS. S-nitrosylation in cardiovascular signaling. Circ Res. 2010;106(4):633–46. Scholar
  87. 87.
    Lai TS, Hausladen A, Slaughter TF, Eu JP, Stamler JS, Greenberg CS. Calcium regulates S-nitrosylation, denitrosylation, and activity of tissue transglutaminase. Biochemistry. 2001;40(16):4904–10. Scholar
  88. 88.
    • Benhar M. Nitric oxide and the thioredoxin system: a complex interplay in redox regulation. Biochim Biophys Acta Gen Subj. 2015;1850(12):2476–84. This review discussess denitrosylating role of Thioredoxin in diverse protein substrates. CrossRefGoogle Scholar
  89. 89.
    Santhanam L, Tuday EC, Webb AK, Dowzicky P, Kim JH, Oh YJ, et al. Decreased S-nitrosylation of tissue transglutaminase contributes to age-related increases in vascular stiffness. Circ Res. 2010;107(1):117–25. Scholar
  90. 90.
    Kim JH, Bugaj LJ, Oh YJ, Bivalacqua TJ, Ryoo S, Soucy KG, et al. Arginase inhibition restores NOS coupling and reverses endothelial dysfunction and vascular stiffness in old rats. J Appl Physiol. 2009;107(4):1249–57. PubMedPubMedCentralCrossRefGoogle Scholar
  91. 91.
    Hamilton CA, Brosnan MJ, McIntyre M, Graham D, Dominiczak AF. Superoxide excess in hypertension and aging: a common cause of endothelial dysfunction. Hypertension. 2001;37(2 Pt 2):529–34. Scholar
  92. 92.
    Taddei S, Virdis A, Ghiadoni L, Salvetti G, Bernini G, Magagna A, et al. Age-related reduction of NO availability and oxidative stress in humans. Hypertension. 2001;38(2):274–9. Scholar
  93. 93.
    van der Loo B, Labugger R, Skepper JN, Bachschmid M, Kilo J, Powell JM, et al. Enhanced peroxynitrite formation is associated with vascular aging. J Exp Med. 2000;192(12):1731–44.PubMedPubMedCentralCrossRefGoogle Scholar
  94. 94.
    Andrawis N, Jones DS, Abernethy DR. Aging is associated with endothelial dysfunction in the human forearm vasculature. J Am Geriatr Soc. 2000;48(2):193–8.PubMedCrossRefGoogle Scholar
  95. 95.
    Gates PE, Strain WD, Shore AC. Human endothelial function and microvascular ageing. Exp Physiol. 2009;94(3):311–6. Scholar
  96. 96.
    Crabtree MJ, Brixey R, Batchelor H, Hale AB, Channon KM. Integrated redox sensor and effector functions for tetrahydrobiopterin- and glutathionylation-dependent endothelial nitric-oxide synthase uncoupling. J Biol Chem. 2013;288(1):561–9. PubMedCrossRefGoogle Scholar
  97. 97.
    Chen CA, Wang TY, Varadharaj S, Reyes LA, Hemann C, Talukder MA, et al. S-glutathionylation uncouples eNOS and regulates its cellular and vascular function. Nature. 2010;468(7327):1115–8. Scholar
  98. 98.
    •• Subramani J, Kundumani-Sridharan V, Hilgers RH, Owens C, Das KC. Thioredoxin uses a GSH-independent route to Deglutathionylate endothelial nitric-oxide synthase and protect against myocardial infarction. J Biol Chem. 2016;291(45):23374–89. This demonstrates that thioredoxin rescued eNOS from glutathionylation during ischemia-reperfusion in a GSH-independent manner. They also found that Trx directly interacts with eNOS and deglutahionylate Cys-691 and Cys-910.PubMedPubMedCentralCrossRefGoogle Scholar
  99. 99.
    Martin E, Berka V, Tsai AL, Murad F. Soluble guanylyl cyclase: the nitric oxide receptor. Methods Enzymol. 2005;396:478–92. Scholar
  100. 100.
    Kloss S, Bouloumie A, Mulsch A. Aging and chronic hypertension decrease expression of rat aortic soluble guanylyl cyclase. Hypertension. 2000;35(1 Pt 1):43–7.PubMedGoogle Scholar
  101. 101.
    Crassous PA, Couloubaly S, Huang C, Zhou Z, Baskaran P, Kim DD, et al. Soluble guanylyl cyclase is a target of angiotensin II-induced nitrosative stress in a hypertensive rat model. Am J Physiol Heart Circ Physiol. 2012;303(5):H597–604. Scholar
  102. 102.
    Huang C, Alapa M, Shu P, Nagarajan N, Wu C, Sadoshima J, et al. Guanylyl cyclase sensitivity to nitric oxide is protected by a thiol oxidation-driven interaction with Thioredoxin1. J Biol Chem. 2017;292(35):14362–70. PubMedCrossRefGoogle Scholar
  103. 103.
    Rahaman MM, Nguyen AT, Miller MP, Hahn SA, Sparacino-Watkins C, Jobbagy S, et al. Cytochrome b5 reductase 3 modulates soluble guanylate cyclase redox state and cGMP signaling. Circ Res. 2017;121(2):137–48. PubMedCrossRefGoogle Scholar
  104. 104.
    Gao XH, Qanungo S, Pai HV, Starke DW, Steller KM, Fujioka H, et al. Aging-dependent changes in rat heart mitochondrial glutaredoxins--implications for redox regulation. Redox Biol. 2013;1(1):586–98. Scholar
  105. 105.
    Burgoyne JR, Prysyazhna O, Rudyk O, Eaton P. cGMP-dependent activation of protein kinase G precludes disulfide activation: implications for blood pressure control. Hypertension. 2012;60(5):1301–8. Scholar
  106. 106.
    Prysyazhna O, Rudyk O, Eaton P. Single atom substitution in mouse protein kinase G eliminates oxidant sensing to cause hypertension. Nat Med. 2012;18(2):286–90. Scholar
  107. 107.
    Fleming I. The factor in EDHF: cytochrome P450 derived lipid mediators and vascular signaling. Vasc Pharmacol. 2016;86:31–40. Scholar
  108. 108.
    Feletou M, Vanhoutte PM. Endothelium-derived hyperpolarizing factor: where are we now? Arterioscler Thromb Vasc Biol. 2006;26(6):1215–25. Scholar
  109. 109.
    Didion SP, Kinzenbaw DA, Schrader LI, Faraci FM. Heterozygous CuZn superoxide dismutase deficiency produces a vascular phenotype with aging. Hypertension. 2006;48(6):1072–9. Scholar
  110. 110.
    Rammos C, Hendgen-Cotta UB, Deenen R, Pohl J, Stock P, Hinzmann C, et al. Age-related vascular gene expression profiling in mice. Mech Ageing Dev. 2014;135:15–23. Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Kumuda C. Das
    • 1
  • Venkatesh Kundumani-Sridharan
    • 1
  • Jaganathan Subramani
    • 1
  1. 1.Department of Translational and Vascular BiologyUniversity of Texas Health Sciences Center at TylerTylerUSA

Personalised recommendations